New York Office | firstname.lastname@example.org
Arthur Tinkelenberg, an Executive Director at Torreya, has 20 years of experience that spans venture capital, corporate finance, basic research, product development, and business development.
Before joining Torreya in 2016, he served as CEO and President of Enumeral Biomedical, an immuno-oncology company that he co-founded in collaboration with MIT and Harvard and brought public in 2014 through a reverse merger and PIPE. Earlier, Arthur was a Partner at Ascent Biomedical Ventures, a venture capital firm investing in early-stage life science companies. He is also an inventor and author of numerous peer-reviewed publications, and has conducted research in lipid biochemistry at Columbia University.
Arthur earned a Ph.D. in molecular genetics from The Rockefeller University, where he studied cell growth regulation and signal transduction as a Rockefeller and National Science Foundation Fellow. He holds a B.A. in biology, with honors, from Grinnell College.
Arthur has served on numerous boards, including Enumeral, Azevan Pharmaceuticals, Ouroboros Medical, Curaseal, Targanox, XLumena, CrossTrees Medical, SpineView, and Cara Therapeutics. He currently sits on the board of directors of NewYorkBio, which advocates for the life sciences industry in New York State.
|Research collaboration and license agreement for |
RIG-I pathway with
Up to $505 million